AUS
NZ
UK
CA
USA
IND
Scancell Holdings PLC (LSE:SCLP) has outlined an ambitious roadmap for the next 18 months, capitalizing on the clinical advancements achieved so far in its cancer immunotherapy initiatives.
Upcoming Milestones
A key early milestone includes the anticipated release of full cohort data for SCIB1 and iSCIB1+ (targeting melanoma) by late 2024 and early 2025. In addition, the company plans to launch a phase II/III registration trial for SCIB1 or iSCIB1+ in 2025. The initial results from the phase II study of SCIB1 have been promising, with 11 out of 13 patients showing at least a partial response, surpassing the targeted overall response rate of 70%.
Focus on Additional Studies
Scancell is also preparing to unveil data from the ModiFY study, which evaluates Modi-1 in combination with checkpoint inhibitors for renal cell carcinoma (RCC), expected in the first half of 2025. This study is part of the company’s broader strategy to advance its innovative therapeutic platforms.
Financial Overview
In its results for the fiscal year ending April 30, Scancell reported a loss of £18.3 million, reflecting significant investment in drug research and development. Importantly, the company concluded the period with £14.8 million in cash, ensuring operational funding through the third quarter of next year.
Strategic Outlook
CEO Professor Lindy Durrant expressed confidence in the company’s trajectory, citing significant clinical and commercial milestones, positive early efficacy data, and a strong financial position to support ongoing strategies. Scancell is also actively exploring partnering or out-licensing opportunities for its GlyMab and AvidiMab platforms, aiming to enhance its market presence and collaboration..
With a clear focus on advancing its clinical programs and maintaining a solid financial footing, Scancell Holdings PLC is well-positioned to make significant strides in the cancer immunotherapy space. The forthcoming data releases and trial initiations will be crucial in validating its innovative approaches and driving future growth.
